The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting

[1]  S. Morrison,et al.  Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity , 2009, Cancer Immunology, Immunotherapy.

[2]  A. García-Sastre,et al.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Florian Steinberg,et al.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. , 2009, Neoplasia.

[4]  R. Alexander,et al.  Cutting Edge: Permissive MHC Class II Allele Changes the Pattern of Antitumor Immune Response Resulting in Failure of Tumor Rejection1 , 2009, The Journal of Immunology.

[5]  J. Xiang,et al.  CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses1 , 2009, The Journal of Immunology.

[6]  S. Xiao,et al.  Immunogenicity of porcine circovirus type 2 capsid protein targeting to different subcellular compartments. , 2008, Molecular immunology.

[7]  M. Disis,et al.  Immune modulation as a therapeutic strategy for non-small-cell lung cancer. , 2008, Clinical lung cancer.

[8]  A. Arnold,et al.  Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy , 2007, Gene Therapy.

[9]  S. Xiao,et al.  C3d enhanced DNA vaccination induced humoral immune response to glycoprotein C of pseudorabies virus. , 2006, Biochemical and biophysical research communications.

[10]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[11]  P. Fournier,et al.  Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus , 2005, Cancer Gene Therapy.

[12]  P. Fournier,et al.  Induction of Interferon-α and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Human Blood Mononuclear Cells by Hemagglutinin-Neuraminidase but Not F Protein of Newcastle Disease Virus , 2002 .

[13]  M. Peeples,et al.  Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. , 2001, Cancer letters.

[14]  T. Todo,et al.  Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  J. Niederkorn,et al.  The role of cytotoxic T lymphocytes in corneal allograft rejection. , 2000, Investigative ophthalmology & visual science.

[16]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[17]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[18]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[19]  Y. Chen,et al.  The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. , 1999, Cancer research.

[20]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[21]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[22]  V. Schirrmacher,et al.  Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[24]  W. Cassel,et al.  Newcastle disease virus as an antineoplastic agent , 1965, Cancer.

[25]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[26]  Li Xi.  Anti-tumor effects of NDV D90 against tumor cells of A549 in vitro , 2008 .

[27]  G. Dyckhoff,et al.  Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. , 2005, Advances in oto-rhino-laryngology.

[28]  J. Sinkovics,et al.  Superinfection of tumors with viruses , 2005, Experientia.

[29]  Dai Jian.  Construction of Newcastle disease virus hemagglutinin-neuraminidase (HN) gene and its antitumor immune response effects , 2000 .

[30]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.